The FDA has declined to review Moderna's application for a new mRNA-based flu vaccine, citing concerns about how the clinical trials were designed. The decision is unusual enough that it was signed by the agency's top biologics official rather than the standard review team — a signal that something broader may be shifting at the agency.
Moderna's vaccine showed promise in testing. It produced stronger antibody responses than existing flu shots, with no safety red flags. The company had already cleared the FDA's initial approval to pursue the project. But when Moderna submitted its licensing application, regulators rejected it without review, arguing that comparing the new vaccine to standard flu shots "does not reflect the best-available standard of care."
That reasoning has drawn pushback from vaccine experts. Dorit Reiss, a law professor at UC Law San Francisco who studies vaccine policy, points out that for adults under 65, the high-dose flu shot the FDA cited as a comparator isn't actually standard care. "The FDA's decision is also false in this regard," she said. The logic matters because it shapes what kind of evidence companies need to gather before they can even ask for approval — and if the goalposts keep moving, fewer companies will bother trying.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxWhat this signals
The timing adds weight to the concern. This decision arrives as the Trump administration has taken other steps to distance itself from vaccines, including pausing full recommendations for roughly one-third of routine childhood immunizations. Experts worry the FDA's move could chill investment in flu vaccine development more broadly. If companies can't predict what evidence will satisfy regulators, the incentive to spend millions on research evaporates.
Moderna has asked for a meeting with the FDA to discuss the refusal. Meanwhile, the company's flu vaccine is already under review in the European Union, Canada, and Australia — a reminder that regulatory pathways aren't uniform, and decisions in one country don't determine outcomes elsewhere.
The question now is whether this represents an isolated call or a pattern. One unusual decision can be explained away. But if the FDA continues to raise the bar for vaccines while other regulatory bodies move forward, it could reshape which vaccines reach which populations first.
